Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Key Points

• To compare the effectiveness of ustekinumab and JAK inhibitors against vedolizumab in ulcerative colitis after anti-TNF failure.
• Compared the efficacy of ustekinumab and JAK inhibitors to vedolizumab
• Focused on steroid-free and biochemical remission rates
• Considered safety profiles for patient selection
• Ustekinumab and JAK inhibitors showed higher rates of steroid-free remission than vedolizumab
• Biochemical remission rates were also significantly better with ustekinumab and JAK inhibitors
• Safety concerns were noted for JAK inhibitors, highlighting the need for careful patient selection